

Arizona Biomedical Research Commission

March 30, 2006

15 South 15th Avenue, Suite 103-A
Phoenix, Arizona 85007

Members Present:

Eileen Bond
Colleen Brophy
Gary Krahenbuhl
Walter Williams
David Landrith
David Jerman

Staff Present:

Dawn Schroeder
James Matthews

The teleconference meeting was called to order by Commissioner Bond, acting Chair, at 10:03 am.

Commissioner Landrith moved that the Commission go into Executive Session to discuss the items on the agenda. Commissioner Brophy seconded.

In open meeting, the following motions and votes were taken.

Commissioner Krahenbuhl moved that the Commission file appropriate patents relating to contract number 8017: Eluding drug resistance in cancer chemotherapy. Commissioner Landrith seconded. The motion was unanimously approved.

Commissioner Landrith moved that the Commission extend contract number 9-036: Molecular therapeutic targeting of MUC1/ β -catenin interactions in invasive breast carcinoma until June 30, 2007 for the amount of \$50,000. Commissioner Krahenbuhl seconded. The motion was unanimously approved.

Commissioner Landrith moved that the Commission file appropriate patents relating to contract number 9-036: Molecular therapeutic targeting of MUC1/ β -catenin interactions in invasive breast carcinoma. Commissioner Brophy seconded. The motion was unanimously approved.

Commissioner Landrith inquired as to the status of legal representation by the Office of the Attorney General. Executive Director Schroeder responded that no recruitment has taken place but that the Office of the Attorney General is familiarizing itself with the work of the Commission and making internal inquiries as to an in-office candidate for the position.

Commissioner Bond made a call to the public.

The meeting adjourned at 10:13 am.

Arizona Biomedical Research Commission

James Matthews
Deputy Director